Also categorized in News:
Hebrew U tech chief seeks balance between academia and industry
x hide permanently

Therapix Biosciences Plans Preclinical Study to Evaluate Opioid-Sparing Effects of Two Innovative Synthetic Cannabinoids

PR Newswire

/PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based treatments, executed a non-exclusive material transfer agreement with Yissum, the technology transfer company of The , for two synthetic cannabinoids synthesized by , Ph.D., Professor of medicinal chemistry at the university and Chairman of the Therapix Scientific Advisory Board. Therapix plans to initiate a preclinical study during the fourth quarter to evaluate the opioid-sparing effect of these compounds in a rat model. The opioid overuse epidemic in was recently declared a public health emergency by President . According to Medical Care, prescription opioid overdose, abuse ...

Mentions: Medicine/Health